U.S. flag

An official website of the United States government

Filters

See more specimen types...

Other countries

Results: 1 to 20 of 79

Tests names and labsConditionsGenes, analytes, and microbesMethods

MVL Vision Panel

Molecular Vision Laboratory
United States
13581028
  • C Sequence analysis of the entire coding region

CACNA1A - repeat expansion analysis

Centogene AG - the Rare Disease Company
Germany
41
  • T Targeted variant analysis

CACNA1A - NGS including CNV analysis

Centogene AG - the Rare Disease Company
Germany
41
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Invitae Leukodystrophy and Genetic Leukoencephalopathy Panel

Invitae
United States
971680
  • D Deletion/duplication analysis

Invitae Neurodevelopmental Disorders Panel

Invitae
United States
404241
  • D Deletion/duplication analysis

Stroke, Cerebral Hemorrhage, Hemiplegia, and Migraine Panel

PreventionGenetics
United States
345159
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Invitae Familial Hemiplegic Migraine Panel

Invitae
United States
217
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Episodic Ataxia Panel

PreventionGenetics
United States
6136
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Invitae Cerebral Palsy Spectrum Disorders Panel

Invitae
United States
638419
  • D Deletion/duplication analysis

Familial Hemiplegic Migraine: gene sequence and deletion/duplication

Ambry Genetics
United States
77
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500, Autosomal dominant; FHM1 (Spinocerebellar ataxia type 6) (MLPA)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • D Deletion/duplication analysis

Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500, Autosomal dominant; FHM1 (Spinocerebellar ataxia type 6) (CACNA1A gene) (Sequence Analysis-All Coding Exons) (Postnatal)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • C Sequence analysis of the entire coding region

Migraine, familial hemiplegic, 1, 141500, Autosomal dominant (Familial or sporadic hemiplegic migraine) (CACNA1A gene) (Sequence Analysis-All Coding Exons) (Postnatal)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • C Sequence analysis of the entire coding region

Migraine, familial hemiplegic, 1, 141500, Autosomal dominant (Familial or sporadic hemiplegic migraine) (MLPA)

Intergen Intergen Genetics and Rare Diseases Diagnosis Center
Turkey
11
  • D Deletion/duplication analysis

Top 99 Genetic Causes of Developmental Delay Panel

PreventionGenetics
United States
17099
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Wole Exome Sequencing for Hemiplegic Migraine, Epilepsy, Ataxia, CADASIL/Small Vessel Disease

Genomics Research Centre Queensland University of Technology
Australia
124
  • C Sequence analysis of the entire coding region

Invitae Mendelian Disorders with Psychiatric Symptoms Panel

Invitae
United States
247163
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region

Invitae Epilepsy Panel

Invitae
United States
442298
  • D Deletion/duplication analysis

Next Generation Sequencing for FHM, EA2, SCA6, CADASIL, Epilepsy

Genomics Research Centre Queensland University of Technology
Australia
94
  • C Sequence analysis of the entire coding region

Familial Hemiplegic Migraine and Alternating Hemiplegia of Childhood Panel

PreventionGenetics
United States
138
  • D Deletion/duplication analysis
  • C Sequence analysis of the entire coding region
  • T Targeted variant analysis

Results: 1 to 20 of 79

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.